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Summary
The principle cause of one of the most prevalent genetic
disorders, autosomal dominant polycystic kidney
disease, involves mutations in the PKD1 gene. However,
since its identification in 1994, only 27 mutations have
been published. Detection of mutations has been
complicated because the greater part of the gene lies
within a genomic region that is reiterated several times
at another locus on chromosome 16. Amplification of
DNA fragments in the repeated part of the PKD1 gene
will lead to coamplification of highly homologous
fragments derived from this other locus. These
additional fragments severely hamper point-mutation
detection. None of the point mutations published to date
are located in the repeated part of the PKD1 gene.
However, we have reduced the problems posed by the
strong homology, by using the protein-truncation test,
and we have identified eight novel mutations, seven of
which are located in the repeated part of the PKD1 gene.
Introduction
Autosomal dominant polycystic kidney disease
(ADPKD) is one of the most frequently inherited dis-
orders, with an estimated incidence of 1/1,000 in the
Caucasian population (Dalgaard 1957). Mutations in
the PKD1 gene account for ∼85% of all ADPKD cases
(Peters and Sandkuijl 1992). The gene was identified in
1994 (The European Polycystic Kidney Disease Con-
sortium 1994). One year later the genomic sequence of
the entire gene and its 14-kb transcript were elucidated
(The American PKD1 Consortium 1995; Hughes et al.
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1995; The International Polycystic Kidney Disease Con-
sortium 1995).
However, few mutations have been found in patients
with ADPKD. To date, 23 small mutations have been
published (The European Polycystic Kidney Disease
Consortium 1994; Peral et al. 1995, 1996a, 1996b;
Turco et al. 1995; Neophytou et al. 1996; Rosetti et al.
1996), in addition to three mutations detectable on
Southern blots (The European Polycystic Kidney Disease
Consortium 1994; Roelfsema et al. 1996a) and one de
novo translocation (The European Polycystic Kidney
Disease Consortium 1994). The main problem involved
here is the very strong homology between the greater
part of the PKD1 gene and another locus, proximal on
chromosome 16p (Germino et al. 1992; The European
Polycystic Kidney Disease Consortium 1994). Only the
3′ end of the PKD1 gene is unique (fig. 1). Of the 23
small mutations published to date, 17 are within the
unique region.
A large-scale screening for point mutations at this
unique part of the PKD1 gene revealed a detection rate
of 10%–15% (Peral et al. 1996b). This suggests that
most mutations will be located in the repeat area. The
homology poses an enormous problem, because all stan-
dard techniques used in point-mutation detection make
use of PCR (Myers et al. 1987; Cotton et al. 1988; Orita
et al. 1989; White et al. 1992). Amplification in the
repeated area will, unfortunately, result in coamplifica-
tion of homologous sequences derived from the proxi-
mal locus. It is extremely difficult to detect a mutated
allele among this large number of wild type–like alleles.
Moreover, the fragments derived from the homologous
proximal locus do not have exactly the same sequence
(The American PKD1 Consortium 1995) and could
therefore result in false positives.
We chose the protein-truncation test (PTT) (Roest et
al. 1993; Roelfsema et al. 1996b) as a solution to these
problems instead of using technically demanding meth-
ods such as either cloning of genomic DNA frompatients
or long-range PCRwith PKD1-specific primers. The PTT
detects translation-terminating mutations on the basis of
coupled transcription/translation reactions of PCRprod-
ucts. The artificially produced proteins represent small
parts of polycystin-1, the PKD1 gene product. After size
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Figure 1 Model of repeated structure of PKD1 gene on chromosome 16p. The top line represents parts of chromosome 16p: the PKD1
gene and a region with strong homology to the gene. A large part of the PKD1 gene, encompassing ∼75% of its coding sequence, lies in a
region that shares very strong homology with a region, reiterated several times, at a proximal locus; six iterations are shown, but the precise
number is unknown. This proximal locus encodes three transcripts, of 20 kb, 17 kb, and 8.5 kb. There is little sequence divergence between
the PKD1 gene and the homologous locus: the homology is estimated to reach 97% (The American PKD1 Consortium 1995; The International
Polycystic Kidney Disease Consortium 1995). The homologous parts are gray shaded, and the unique parts are blackened. Depicted in detail
is the PKD1 gene, with its 46 exons and the ∼14-kb transcript. The PCR fragments used in this study are indicated on the DNA and RNA
level. Fragments that could be amplified directly from genomic DNA are indicated as diagonally hatched boxes.
determination by SDS-PAGE, truncated proteins that
correspond to premature stops in the PCR product can
then be detected. The PTT detects aberrant proteins in-
stead of aberrant DNA fragments and is a very sensitive
method.
Recently, the first mutations in the repeated part of
the PKD1 gene were found by the PTT or by a nonistopic
RNase-cleavage assay in combination with long-range
PCR and an anchored PKD1-specific primer (Peral et al.
1997). We report mutations detected in the repeated part
by only the PTT. The gene comprises either 12,906 bases
of coding sequence (Hughes et al. 1995) or 12,909 bases
of coding sequence (The International Polycystic Kidney
Disease Consortium 1995). In our screening we covered
9,412 contiguous bases from the 3′ end onward. In total,
eight mutations were found, seven of which are located
in the repeated region.
Subjects and Methods
Family Selection and Isolation of DNA and RNA
In this study we analyzed RNA from a group of 20
individuals and DNA from 135 individuals of Dutch
origin, all of whom were diagnosed as having ADPKD.
When linkage analysis could be performed and the mu-
tation was found not to be linked to the PKD1 locus,
the family was not included in this study. Of the 135
individuals, 36 are single patients.
DNA was isolated from peripheral blood by use of
standard procedures (Breuning et al. 1990). RNA was
extracted from peripheral blood as well. Total RNAwas
isolated with RNAzol, according to the manufacturer’s
instructions (Cinna; Biotecx Laboratories).
1046 Am. J. Hum. Genet. 61:1044–1052, 1997
Amplification of DNA and RNA
RNA was reverse transcribed by use of Superscript
reverse transcriptase (Life Technologies). The cDNA syn-
thesis was either randomly primed or primed with the
KG8BP1A oligonucleotide, which anneals to a specific
sequence in the 3′ UTR of the PKD1 transcript (Peral et
al. 1994). In each reaction cDNA was used, synthesized
from ∼75 ng of total RNA.
Total genomic DNA was used for PCR on DNA. Con-
centrations were 200–300 ng in each reaction.
The PCR was performed in 50-ml reactions with Taq
DNA Polymerase (Life Technologies). PCR buffer con-
tained 50 mM KCl, 10 mM Tris-HCl pH 8.9, 100 mg
of BSA, 0.01% gelatin, 400 pmol of each dNTP, and
10% glycerol. In all reactions 10 pmol of each primer
was used. All fragments could be amplified with 1.5 mM
MgCl2, except for fragment G, for which 2.0 mM was
used. The PCR was performed on a Hybaid Omnigene
thermocycler, in 40 cycles. The forward primer contains
a T7 phage promoter sequence and eukaryotic transla-
tion-initiation sequence (Kozak 1984), needed for the in
vitro transcription/translation (Roest et al. 1993). The
primers used to generate the fragments for the in vitro
transcription/translation are listed in table 1. Amplifi-
cation on RNA necessitated a booster PCR. The first
PCR was performed with forward primers that were
located 2–10 bp toward the 5′ end and that did not have
a tail with the T7 promoter and Kozak consensus
sequence.
PTT and Sequence Analysis
The PTT analyzes PCR fragments representing part
of the open reading frame. The fragments, preferably
1500 bp, are translated into small proteins. Therefore,
amplification with genomic DNA as target can only be
done with large exons, limiting our screening to exons
15 and 23. The remaining exons were amplified from
RNA, by reverse transcriptase–PCR (RT-PCR).
The PTT was performed according to the method of
Roest et al. (1993). All PCR products were analyzed on
2.5% agarose gels. In each in vitro transcription/trans-
lation reaction, 3.5 ml of PCR product was used. In
addition to 6.25 ml of lysate, T7 polymerase, leucine-
depleted amino acids, and buffer were added, all from
the TNT Coupled Reticulocyte Lysate kit (Promega). In
order to radioactively label the proteins, tritium-labeled
leucine (Amersham) was added. The reactions were per-
formed for 60 min at 30C. Size determination of the
reaction products was performed on a 14% SDS-poly-
acrylamide gel. Typically, 28 samples were loaded onto
one gel. The gel was dehydrated by a wash in dimethyl
sulfoxide (DMSO), followed by an incubation in
DMSO/2,5-diphenyloxazole and a final wash in water.
The gel was then dried on a vacuum slab-gel dryer and
subsequently was autoradiographed by use of Kodak X-
Omat film. Truncated proteins can be seen as strong
bands with an intensity that nearly equals and sometimes
even exceeds the intensity of the wild-type band. Ad-
ditional fainter bands can also be seen on film and are
probably caused by second translation-initiation sites,
present in all samples, and mutations during PCR. In
order to distinguish truncated proteins caused by true
mutations, x10 samples were loaded onto one gel. In
addition, all positive individuals were analyzed again, in
duplicate.
The PTT results in weak signals when PCR fragments
with a short open reading frame are used. Fragment A
in our study has a short open reading frame and was
therefore used only for the individuals who were ana-
lyzed with RT-PCR as well, even though fragment A
could be amplified on genomic DNA. After an exposure
time of 2 wk, results were obtained for this group of
patients.
PCR fragments were cloned with the pGEM-T vector
(Promega) or with pBluescript. The clones were gridded
in a square. The clones of each row and column were
pooled. These pools, containing five to seven clones,
were analyzed by the PTT. The positive rows and col-
umns indicate the clones with the mutated allele. Sub-
sequent sequence analysis was performed either with the
automated-laser fluorescent-DNA sequencer (ALF) or
manually with either the Amplicycle kit (Perkin Elmer)
or the Sequenase kit (USB), according to the manufac-
turer’s protocol. When it was possible, the sequence data
were confirmed by restriction analysis. The mutant se-
quence of PK167 is based on two clones; the mutant
sequences of PK56 and PK71 are each based on one.
Results
We screened exons 16–46 by RT-PCR, using 11 over-
lapping primer pairs, called “A”–“K,” which together
cover 6,336 bases (fig. 1). Each fragment is X1 kb. In
our experience, it is difficult to amplify larger fragments.
Not only is the efficiency reduced, but extra products
are generated as a result of faulty annealing of primers.
Amplification of genomic DNA is not hampered by
these problems. A booster PCR is not needed, and much
larger PCR products can be generated. Exon 15 is ideal
for this purpose. We covered most of exon 15 by using
three PCR fragments, called “L,” “M,” and “N,” which
are 0.8 kb, 1.7 kb, and 1.3 kb, respectively (fig. 1).
To test the possibility of genomic DNA–based screen-
ing, we first performed the PTT in combination with
genomic PCR on patient PK153-1, amplifying exon 23.
We had already found a truncation with fragment H,
corresponding to exon 23, by using RT-PCR on RNA
from this patient. Despite the fact that a genomic PCR
results in a relatively greater proportion of homologous
sequences, the truncated protein could be detected as
clearly as it could be by use of RT-PCR. We screened
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Table 1
Primers Used in Present Study
FRAGMENT
PRIMER
Forward Forward with Taila Reverse
A TGACCGACTCAACCAGGCCACA CTCAACCAGGCCACAGAGGACG CGCAGGCCCCTCAGCCCTAGT
B CGCCGCTTCACTAGCTTCGAC GACCAGGTGGCGCACGTGAGCT GGCCTTGCAGGCTGTGCAGCTG
C GGCCCCAGGGTCCACACGTGC CACACGTGCTCGGCCGCAGG ACGCTCCAGAGGGAGTCCAC
D CAGGTCCTTGCCGAGGGGGTC GTCAGCAGCCCAGCCCCTACCC GGACTCTCCCAGCCAACGTCG
E TGGCTCTCCATATGGGACCGG AGCCGTTTCACTCGCATCCAG CGTTTCCATGTGGGTGTCTTGGG
F TCTTCGTGCCCCCAAGCCATGTC CGCTTTGTGTTTCCTGAGCCGA AGTCGCCAACAGCCCCGTACC
G GGTCCAGCCCCAGGCCTCCG GTCGGTGCTGTGGTCACCCTG ACTGGTCCAGCTTGTGCAGGATG
H CTCATCCACCTGGCCAGCTCGG TAGTGGCCGTCCAGCAGCGT
I GCTGTCGCCAGGGCCACTGC CGCTGTCGCCAGGGCCACTGC CCAGCGTCAGGGGCTCCTCGT
J GGCTGGCGGCTGGCGTGGAGTA CTGGCGGCTGGCGTGGAGTACA GGGCTCTGGGAGGGTGATGGC
K AGTACCGCTGGGAGGTGTATCG TACCGCTGGGAGGTGTATCGC ACCTTGGTGGTGAGGGCGTG
L AACTTCACAGCCCGCGTGCAG TGATGGGCACCAGGCGCTCG
M GATCTGGGGGACGGTGGGTGG GAGCGGTTGGTGAAGCAGG
N ACGTGGGACTTCGGGGACGG AGGGATGGGCGTGCAGCGGT
a The tail consists of a T7 phage promoter and a eukaryotic translation-initiation site (sequence not shown).
genomic DNA from other individuals, but only
PK153-1 has a mutation in exon 23.
Screening of exon 15 was performed with the same
ease that characterized the screening of exon 23, except
for fragment N, which showed a slightly complicated
banding pattern on autoradiographs. Sequence diver-
gence in some part of the region homologous to fragment
N results in a premature stop. This leads to a truncated
protein in all individuals. Performing the PTT on DNA
from the somatic-cell hybrid HY145.19, which contains
only the PKD1 locus and not the homologous proximal
locus (Ceccherini et al. 1989), proved that the translation
stop originates from the homologous locus. This trun-
cated protein causes a complex pattern (fig. 2, right-hand
gel, lanes C, PK71, and PK44). Nevertheless, mutations
can be detected: two truncated proteins were clearly vis-
ible after screening of this fragment.
Screening the RNA of 24 affected individuals revealed
two mutations (table 2 and fig. 2). One of these is the
aforementioned mutation in exon 23; the other is a base
substitution found both with fragment B and with frag-
ment C, in exon 44. The screening of genomic DNAwas
performed on 135 affected individuals, and six addi-
tional mutations in exon 15 were detected (table 2 and
fig. 2). One mutation was found in two individuals from
separate families living in the same town, who therefore
are likely to be related.
After the initial detection of a truncated protein in an
individual, other family members were analyzed as well.
However, additional family members were not available
for all individuals with positive PTT results. Family 5,
probably connected to family 133, is a large pedigree
with x75 additional family members. Family 167 is also
reasonably large, with 12 members, 7 of whom are af-
fected. Family 71 has five members: the two parents, one
of whom is affected, and three children, one of whom
is affected. Family 55 consists of two affected brothers.
Cosegregation of truncated proteins with the diseasewas
always seen in the additional affected members and
never in unaffected individuals. However, the possibility
remains that the mutation causing the truncation is pres-
ent at the homologous proximal locus rather than in the
PKD1 gene. Therefore, we performed haplotype analysis
on families 5, 71, 133, and 167, with markers HBAP1
(Fougerousse et al. 1992), KG8 (Snarey et al. 1994),
CW2 (Peral et al. 1994), D16S423 (Weissenbach et al.
1992), D16S509 (Gyapay et al. 1994), D16S406 (Weis-
senbach et al. 1992), and D16S3103 (Dib et al. 1996).
These markers range from the PKD1 locus toward the
homologous proximal locus. HBAP1 is distal to the
PKD1 gene, and KG8 is located in the 3′ UTR of the
PKD1 transcript. The other markers are proximal from
the PKD1 gene, marker D16S3103 being close to the
homologous proximal locus. The analysis revealed re-
combination events between the homologous proximal
locus and the PKD1 gene in selected individuals from
families 5 and 167 (fig. 3). These recombination events
prove that their truncated proteins are derived from the
PKD1 locus.
Premature stops in the repeated part of the gene can
be detected by the PTT, without difficulty. However, se-
quence analysis of the fragments cannot be done by di-
rect sequencing. Direct sequencing is hampered by the
abundance of homologous fragments (fig. 4). Therefore,
PCR fragments were cloned. For each fragment, 30–49
clones were divided into pools in such a way that each
clone was present in two separate pools. The cloned
fragments were analyzed with the PTT. This procedure
enabled us to identify those clones that resulted in a
truncated protein with the same size as that of the trun-
cated protein from the patient. These clones were se-
quenced either manually or with an automated se-
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Figure 2 A, Model of polycystin-1, the PKD1 gene product, showing positions of mutations presented in this study. The patients indicated
by an asterisk (*) have mutations that could not be confirmed by haplotype analysis. Their mutations could also derive from the homologous
locus. The protein model was constructed on the basis of predictions by Hughes et al. (1995) and Moy et al. (1996). The part of polycystin-
1 surrounded by a dotted-line box is encoded by the unique 3′ end of the transcript, and the remainder is encoded by the duplicated part. B,
Panel of selected fragments from different SDS-PAGE gels. Truncated proteins, indicated by arrowheads, are recognizable in lanes containing
samples from patients. The wild-type proteins vary in size but, for clarity, are shown at the same height. C  control. Additional, faint bands
can be seen on the gels; these are probably caused either by second translation-initiation sites or by mutations during the PCR.
Table 2
Mutations in the PKD1 Gene
Family/families Mutation Positiona PCR Fragment(s) Exon Restriction Site(s)b Family Member Tested
162 GrA 12036 B, C 44 Sau3AI creation/AvaII loss 4
153 CrT 8692 H 23 AvaII loss 1
56 Deletion of 7 bp 6574–6580 L 15 1
5, 133 GrA 5622 M 15 HinfI creation 34
55 Unknown M 15 2
167 Deletion of A 5014 M 15 8
71 Deletion of 2 bp 4036/4042c N 15 5
44 Deletion of T 3866 N 15 BglII creation 4
a According to the open reading frame presented by The International Polycystic Kidney Disease Consortium (1995).
b Only restriction sites tested on PCR fragments derived from genomic DNA are listed.
c Position cannot be determined precisely.
quencer. The PTT detects only translation-terminating
mutations. Therefore, all mutations that we found are
either base substitutions leading to a stop codon or
frameshifts. The sequence of four mutations revealed
small deletions leading to frameshifts. The precise lo-
cation of the mutation in family 71, a deletion of C and
A in a sequence (ACACACA) at positions 4036–4042,
cannot be determined. Base substitutions were found in
three individuals. The sequence analysis of the mutation
in PK55 is in progress (table 2).
The mutant sequence was compared with the wild-
type sequence, to determine the loss or creation of a
restriction site. PCR fragments derived from genomic
DNA from the patients were digested if a site was lost
or gained. However, restriction enzymes that cut DNA
very frequently are not practical for this purpose, be-
cause the aberrant restriction fragments will be over-
shadowed by the many other fragments that these en-
zymes produce. The restriction sites used to confirm
mutations are listed in table 2.
Discussion
We successfully applied the PTT to detect translation-
terminating mutations in the repeated area of the PKD1
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Figure 3 A, Pedigree of family 167, with haplotypes constructed
of markers distal to the PKD1 gene, toward the proximal homologous
locus. The haplotype cosegregating with ADPKD is blackened. The
haplotypes of individuals 4 and 11 are the result of a recombination
event between the PKD1 gene and the homologous proximal locus.
The precise breakpoint of the recombination in individual 11 is not
clear, because his parent is not informative for marker D16S423. A
third recombination event must have occurred in this family as well,
because the haplotype of individual 5 is recombined compared with
those in the other branch of the family. B, SDS-PAGE gel with the in
vitro translation products from family 167. All affected individuals
show truncated proteins.
Figure 4 A, Comparison between direct sequence of PCR frag-
ment H of patient 153-1 and clone of PCR fragment carrying the
mutation in this patient. A very small peak indicating a thymine can
be seen in the direct sequence, but it is almost completely overshad-
owed by the cytosine peak. B, HinfI digest of a PCR product on an
agarose gel. The mutation in families 5 and 133 creates a HinfI site
that produces two very weak bands, compared with the enormous
amount of DNA from the wild type–like sequence. The PCR was
performed on genomic DNA from two affected individuals, one each
from families 5 and 133. N  healthy individual serving as a negative
control; and C  PCR product derived from a clone carrying this
particular mutation, used as a positive control.
gene. Mutation detection in the repeated part of the
PKD1 gene is probably impossible with most standard
methods, without cloning, long-range PCR, or PKD1-
specific primers. Methods such as denaturing gradient-
gel electrophoresis (Myers et al. 1987), SSCP analysis
(Orita et al. 1989), chemical cleavage of mismatch (Cot-
ton et al. 1988), and heteroduplex analysis (White et al.
1992) rely on detection of aberrantly migrating DNA
fragments. The DNA fragments from mutations are
likely to be overshadowed by the enormous abundance
of the homologous sequences. The procedure presented
in the present paper does not require PKD1-specific
primers or long-range PCR (Barnes 1994). However, to
characterize the mutations, cloning and subsequent
screening of PCR fragments are needed.
The PTT is limited to detection of translation-termi-
nating mutations. Therefore, missense mutations, caus-
ing amino acid substitutions, cannot be detected. In the
case of PKD1 we have used this fact, which otherwise
would be a limitation, to our advantage. The PTTmisses
the sequence variants derived from the homologous lo-
cus. A procedure for detection of missense mutations
will probably be technically demanding. Moreover, the
screening can be hampered by polymorphisms. There-
fore, we chose to screen affected individuals for pre-
mature stops, as the first step.
The proportion of mutations identified in our screen-
ing is not very high. To a certain extent this is due to
genetic heterogeneity, since we could not establish link-
age with the PKD1 locus in all of the families that we
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studied. However, genetic heterogeneity can account
only for a relatively small number of cases; therefore,
there must be other explanations as well. Missense mu-
tations will not be found, and, if ADPKD is caused by
a high frequency of missense mutations, this will account
for the low proportion. However, to date, only one pos-
sible missense mutation at the unique part has been pub-
lished (Peral et al. 1996b). Alternatively, mutations may
cluster in a PKD1 region that we either did not screen
extensively or did not screen at all. A similar effect could
be caused by a high frequency of only a few mutations
in our patients. These mutations would then remain to
be identified. Furthermore, there can be various other,
less obvious explanations. For example, inversions may
occur between the PKD1 gene and its homologous re-
gion, similar to the mutation found in one-half of the
individuals with hemophilia A (Naylor et al. 1993).
However, FISH using two cosmids flanking the PKD1
gene in x10 ADPKD patients has not revealed any ev-
idence for inversions (J. G. Dauwerse, personal com-
munication ).
ADPKD is characterized by the formation of multiple
cysts in the kidneys, cysts that grow during the course
of a lifetime (Dalgaard 1957). Cysts can occur in other
organs, particularly in the liver (Milutinovic et al. 1980;
Gabow et al. 1984) but also in the pancreas and spleen
(Milutinovic et al. 1989). Furthermore, patients have a
higher risk for intracranial aneurysms (Chapman et al.
1992). Cardiac valvular abnormalities (Leier et al. 1984;
Hossack et al. 1988) and colonic diverticula have been
reported as well (Scheff et al. 1980). A striking aspect
of ADPKD is that a minority, 1%–2%, of all nephrons
are involved in cyst formation (Scheff et al. 1980). Nev-
ertheless, all affected individuals will develop cysts in the
kidney, but the extrarenal manifestations are subject to
much inter- and intrafamilial variation. Although the
PKD1 and PKD2 genes have both been identified (The
European Polycystic Kidney Disease Consortium 1994;
Mochizuki et al. 1996), it is not clear how the symptoms
are caused. A second-hit model has been proposed to
explain both the variability in phenotype and the fact
that most nephrons remain apparently normal (Reeders
1992). Other models explaining the dominant nature of
the disease include either a dominant-negative effect
from the mutated allele or the lack of one functional
copy of the gene (i.e., haploinsufficiency). Most pre-
mature translation stops that we have found predict
small proteins, with a complete removal of the predicted
integral membrane and cytoplasmic part of polycystin-
1. Whether such small proteins have a biological role
remains to be established. Not all mutations found lead
to small proteins. The mutation in family 162 is a stop
codon in exon 44, leaving the greater part of polycystin-
1 intact. Others studies also have shown mutations in
exon 44 (Turco et al. 1995; Neophytou et al. 1996;
Rosetti et al. 1996). Peral et al. (1996b) have detected
the mutation closest to the 3′ end of the transcript. This
mutation causes a stop in exon 46, removing only 76
amino acids, which clearly indicates that this part has
an important function. Mutations leaving the greater
part of polycystin-1 intact can still lead to severe poly-
cystic kidney disease, as has been shown by a case of
infantile onset of the disease caused by a translation stop
in exon 41 (Peral et al. 1996a).
Recently, evidence for somatic mutations in the PKD1
gene of epithelial cells of cysts has been presented (Qian
et al. 1996). These mutations, occurring in the normal
copy of the PKD1 gene, could be a second hit, leading
to cyst formation. The mutations were deletions in eight
cysts, found by detection of loss of heterozygosity of
two intragenic polymorphic markers 2.5 kb apart in the
unique region of the PKD1 gene, and a 2-bp deletion in
one cyst. These nine somatic mutations were found in
a total of 46 cysts, which means that the other cysts are
still to be accounted for. Perhaps mutations will be found
in other parts of the gene.
The apparent stochastic nature of renal cyst formation
and other symptoms of ADPKD could be explained by
a second-hit model. However, several other characteri-
zations of ADPKD cannot be explained. Despite the in-
trafamilial variation, there is a recurrence risk for early
onset of ADPKD in some families (Zerres et al. 1993).
Recurrence of early onset has been observed in family
5 (Eulderink and Hogewind 1978), in which the mu-
tation has now been characterized. Another feature of
ADPKD is the formation of massive hepatic cysts, which
is predominantly a disorder in women (Gabow et al.
1990). These findings suggest that other factors besides
a second hit are significant in cyst formation. Genetic
modifiers may influence the cause of ADPKD. Possibly
this is the case in deletions removing or disrupting both
the TSC2 gene and the PKD1 gene, causing severe early-
onset renal cyst formation (Brook-Carter et al. 1994).
Cyst formation is a complex process, and the eluci-
dation of this process, which includes mutation analysis,
will probably take some time. Mutation detection in the
repeated part of the PKD1 gene is now possible, at least
for translation-terminating mutations. A procedure for
detection of all types of mutations will be the next im-
portant step.
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